
Sign up to save your podcasts
Or
With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear the country is poised to play a major role in life sciences for the foreseeable future.
In this week’s episode of "The Top Line," we trace China’s ascent in R&D and drug discovery and examine how U.S. and European drugmakers are capitalizing on the momentum through a surge in licensing activity.
Fierce Pharma’s Fraiser Kansteiner sits down with Mark Lansdell, director at Evaluate, to break down the policies fueling China’s growth, how global companies are engaging with Chinese assets and which modalities and indications are commanding the most attention.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
3.8
88 ratings
With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear the country is poised to play a major role in life sciences for the foreseeable future.
In this week’s episode of "The Top Line," we trace China’s ascent in R&D and drug discovery and examine how U.S. and European drugmakers are capitalizing on the momentum through a surge in licensing activity.
Fierce Pharma’s Fraiser Kansteiner sits down with Mark Lansdell, director at Evaluate, to break down the policies fueling China’s growth, how global companies are engaging with Chinese assets and which modalities and indications are commanding the most attention.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
1,714 Listeners
378 Listeners
1,040 Listeners
976 Listeners
1,795 Listeners
378 Listeners
121 Listeners
317 Listeners
163 Listeners
865 Listeners
88 Listeners
30 Listeners
144 Listeners
18 Listeners
50 Listeners